Bacterial detection in platelet components and the rationale for pathogen inactivation: A blood center perspective

Journal of Clinical Apheresis

Volumn 20, Issue 2, 2005, Pages 117-122

  Benjamin, Richard J ^a  

^a AMERICAN RED CROSS   (United States)

Author keywords

Bacterial detection; Intercept ; Pathogen inactivation; Platelets

Indexed keywords

BACTERIUM CONTAMINATION; BACTERIUM CULTURE; BACTERIUM DETECTION; BLOOD ANALYSIS; BLOOD BANK; BLOOD SAMPLING; BLOOD STORAGE; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS; EVALUATION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; QUALITY CONTROL; REPRODUCIBILITY; SHELF LIFE; TECHNIQUE; THROMBOCYTE; THROMBOCYTOPHERESIS; UNITED STATES; VALIDATION PROCESS; WEST NILE FLAVIVIRUS;

BACTERIA; BACTERIAL INFECTIONS; BACTERIOLOGICAL TECHNIQUES; BLOOD BANKS; BLOOD PLATELETS; HUMANS; PLATELET TRANSFUSION;

EID: 24744460528     PISSN: 07332459     EISSN: None     Source Type: Journal    
DOI: 10.1002/jca.20041     Document Type: Conference Paper

References (16)

1. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda AA, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife A, Lin L, Buchholz DH, Conlan MG. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004;104:1534-1541. Epub 2004 May 11.
2. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-2433. Epub 2002 Nov. 27.
3. Brecher ME, Hay SN, Rothenberg SJ. Monitoring of apheresis platelet bacterial contamination with an automated liquid culture system: a university experience. Transfusion 2003;43:974-978.
4. Corash L. Helinx technology for inactivation of infectious pathogens and leukocytes in labile blood components: from theory to clinical application. Transfus Apheresis Sci 2001;25:179-181.
5. Knutson F, Alfonso R, Dupuis K, Mayaudon V, Lin L, Corash L, Hogman CF. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang 2000;78:209-216.
6. Georgsen J. International forum: 5. Vox Sang 2003;85:229-230.
7. Grass JA, Hei DJ, Metchette K, Cimino GD, Wiesehahn GP, Corash L, Lin L. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998;91:2180-2188.
8. Grass JA, Wafa T, Reames A, Wages D, Corash L, Ferrara JL, Lin L. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999;93:3140-3147.
9. Leitman SF, Tisdale JF, Bolan CD, Popovsky MA, Klippel JH, Balow JE, Boumpas DT, Illei GG. Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus. Transfusion 2003;43:1667-1671.
10. Jordan CT, Saakadze N, Newman JL, Lezhava LJ, Maiers TT, Hillyer WM, Roback JD, Hillyer CD. Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet A light inactivates free and latent cytomegalovirus in a murine transfusion model. Transfusion 2004;44:1159-1165.
11. Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion- transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003;101:4195-4200.
12. Detection of West Nile virus in blood donations: United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:769-772.
13. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002;42:975-979.
14. AuBuchon JP, Sandler SG, Fang CT, Dodd RY. American Red Cross experience with routine testing for hepatitis B core antibody. Transfusion 1989;29:230-232.
15. Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang 2004;86:83-91.
16. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelettransfusions. N Engl J Med 1997;337:1861-1869.